Assessment of the Correlation between Disease Activity and Serum Biomarker Anti-MCV and IL6 in Iraqi Patients with Rheumatoid Arthritis
DOI:
https://doi.org/10.32007/jfacmedbaghdad.6632359Keywords:
Anti-mutated citrullinated vimentin, Autoantibody, cytokines, IL6, Rheumatoid arthritisAbstract
Background: Rheumatoid arthritis is an autoimmune disease characterized by autoantibodies against citrullinated antigens. The anti-cyclic citrullinated peptide test is commonly used to diagnose rheumatoid arthritis, whereas the anti-mutated citrullinated vimentin is another anti-citrullinated antibody that reacts with mutated citrullinated vimentin. Anti-mutated citrullinated vimentin antibodies have been suggested as a superior early arthritis diagnostic marker.
Objectives: This study aimed to evaluate the levels of IL6 and anti-mutated citrullinated vimentin biomarkers as well as to determine their potential correlation with disease activity in rheumatoid arthritis Iraqi patients.
Methods: The study included an overall sample of 120 individuals who were recruited from the Department of Rheumatology at Baghdad Teaching Hospital in Baghdad, Iraq, during the period from late August 2023 to early October 2023. They were subdivided into two primary groups. The first group consisted of 60 individuals diagnosed with RA who were further categorized based on disease activity. The second group consisted of 60 healthy individuals as controls. The age range of the participants was between 20 and 79 years. An enzyme-linked immunosorbent test was used to evaluate the blood level of anti-MCV and IL-6.
Results: There was no significant correlation between anti-mutated citrullinated vimentin and disease activity(p-value:0.374) also IL-6 and disease activity(p-value:0.792) but our findings showed there is a statistical accusation between Erythrocytes Sedimentation Rate, and C-reactive protein with disease activity(p-value:0.013 and 0.025) also a high positive correlation between anti-mutated citrullinated vimentin and duration of disease and anti-mutated citrullinated vimentin with Rheumatoid factor and no significant correlation between anti-mutated citrullinated vimentin and IL6.
Conclusion: anti-mutated citrullinated vimentin autoantibody shows a high correlation with the duration of disease and a positive correlation with Rheumatoid factor and has no significant correlation with disease activity.
Received: March 2024
Revised: June, 2024
Accepted: July, 2024
Downloads
References
Klareskog L, Rönnelid J, Saevarsdottir S, Padyukov L, Alfredsson L. The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. Journal of Internal Medicine. 2020;287(5):514-33. https://doi.org/10.1111/joim.13058
Yi X. Observation on Application Effect of Personalized Nursing Intervention in Patients with Rheumatoid Arthritis. Chinese Journal of Medical Sciences. 2020;10:121-3. https://doi.org/10.4236/ym.2023.71002
Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nature Reviews Rheumatology. 2020;16(11):628-44. https://doi.org/10.1038/s41584-020-0503-4
Maranini B, Bortoluzzi A, Silvagni E, Govoni M. Focus on sex and gender: what we need to know in the management of rheumatoid arthritis. Journal of personalized medicine. 2022;12(3):499. https://doi.org/10.3390/jpm12030499
Tsetseri M-N, Silman AJ, Keene DJ, Dakin SG. The role of the microbiome in rheumatoid arthritis: a review. Rheumatology Advances in Practice. 2023;7(2):rkad034. https://doi.org/10.1093/rap/rkad034
van Delft MA, Huizinga TW. An overview of autoantibodies in rheumatoid arthritis. Journal of autoimmunity. 2020;110:102392. https://doi.org/10.1016/j.jaut.2019.102392
Iyengar KP, Vaish A, Nune A. Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance. Journal of Clinical Orthopaedics and Trauma. 2022;24:101729. https://doi.org/10.1016/j.jcot.2021.101729
Volkov M, van Schie KA, van der Woude D. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunological reviews. 2020;294(1):148-63. https://doi.org/10.1111/imr.12829
Mohammed HS, Ahmed GH, Tawfik NM, Sayed SK, Ahmed AS. Anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis; diagnostic utility and association with deformities and disease activity. Egypt J Immunol. 2023;30(1):105-15. https://doi.org/10.55133/eji.300111
Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine. 2020;217(5). https://doi.org/10.1084/jem.20190347
Yip RML, Yim CW. Role of interleukin 6 inhibitors in the management of rheumatoid arthritis. JCR: Journal of Clinical Rheumatology. 2021;27(8):e516-e24. https://doi.org/10.1097/RHU.0000000000001293
Mohammed AM, Zayni SM, AL-Anee MM, Corial FI, Al-Rubaee A. Diagnostic and predictive values of IL-6 in a group of Iraqi patients with rheumatoid arthritis. Journal of the Faculty of Medicine Baghdad. 2023;65(2). https://doi.org/10.32007/jfacmedbagdad.2044
Rashid MK. Prevalence Rate of Rheumatoid Arthritis among Patients Attending Rheumatology Consultation Clinic at Baquba Teaching Hospital. Diyala Journal of Medicine. 2023;24(1):54-65. https://doi.org/10.26505/DJM.24016890831
Pertsinidou E, Manivel VA, Westerlind H, Klareskog L, Alfredsson L, Mathsson-Alm L, et al. Rheumatoid arthritis autoantibodies and their association with age and sex. Clin Exp Rheumatol. 2021;39(4):879-82. https://doi.org/10.55563/clinexprheumatol/4bcmdb
Tao W, Concepcion AN, Vianen M, Marijnissen AC, Lafeber FP, Radstake TR, et al. Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis. Arthritis & Rheumatology. 2021;73(2):212-22. https://doi.org/10.1002/art.41516
Buckman TA, Sakyi SA, Yeboah-Mensah K, Antwi MH, Darban I, Owusu-Brenya L, et al. Demographic, Clinical Profile of Rheumatoid Arthritis Patients and Their Association with Disease Severity in Ghana. International Journal of Rheumatology. 2024;2024(1):6639079. https://doi.org/10.1155/2024/6639079
Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;5(10):e594-e610. https://doi.org/10.1016/S2665-9913(23)00211-4
Albarzinji N, Ismael SA, Albustany D. Association of rheumatoid arthritis and its severity with human leukocytic antigen-DRB1 alleles in Kurdish region in North of Iraq. BMC rheumatology. 2022;6:1-5. https://doi.org/10.1186/s41927-021-00229-9
Lee Y, Bae S, Song G. Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis. Zeitschrift fur Rheumatologie. 2015;74(10):911-8. https://doi.org/10.1007/s00393-015-1598-x
El Shazly RI, Hussein SA, Raslan HZ, Elgogary AA. Anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis patients: Relation to disease activity and manifestations. The Egyptian Rheumatologist. 2014;36(2):65-70. https://doi.org/10.1016/j.ejr.2013.12.009
Nass FR, Skare TL, Goeldner I, Nisihara R, Messias-Reason IT, Utiyama SR. Analysis of four serum biomarkers in rheumatoid arthritis: association with extra articular manifestations in patients and arthralgia in relatives. Revista Brasileira de Reumatologia. 2017;57:286-93. https://doi.org/10.1016/j.rbr.2015.11.002
Nigm DA, Abdel-Lateef HH, Hashim J, Kamal D. Antibodies against a mutated citrullinated vimentin in patients with rheumatoid arthritis. The Egyptian Journal of Immunology. 2022;29(4):184-94. https://doi.org/10.55133/eji.290418
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis & Rheumatism. 2008;58(1):36-45. https://doi.org/10.1002/art.23188
Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Alkaabi J. Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Omani patients with rheumatoid arthritis. International Journal of Rheumatology. 2012;2012. https://doi.org/10.1155/2012/285854
Reyes-Castillo Z, Palafox-Sánchez C, Parra-Rojas I, Martínez-Bonilla G, del Toro-Arreola S, Ramírez-Dueñas M, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clinical & Experimental Immunology. 2015;182(2):119-31. https://doi.org/10.1111/cei.12677
Matsumoto H, Fujita Y, Asano T, Matsuoka N, Temmoku J, Sato S, et al. Association between inflammatory cytokines and immune–checkpoint molecule in rheumatoid arthritis. PLoS One. 2021;16(11):e0260254. https://doi.org/10.1371/journal.pone.0260254
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Dania A. Ali, Muhammad M. AL-Anee, Nizar A. Al-Anee, Adnan A. Alrubaye
This work is licensed under a Creative Commons Attribution 4.0 International License.
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.
How to Cite
Creative Commons Attribution 4.0 International license..
